Government Pharma Investigations Target Pricing, Opioids, Trade Practices
Executive Summary
While DOJ probes have declined in last few years, 13 of top 25 pharma companies are dealing with ongoing inquiries of marketing and pricing practices.
You may also be interested in...
Novartis To Make Its Medical Education Programs Virtual Under DOJ Settlement
Two settlements totaling $729m resolve kickback claims related to speaker programs and copay charities; Novartis will limit payments to healthcare professionals for providing medical education under a new corporate integrity agreement.
DOJ Casting Wider Net In Pharma Kickback Probes
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.
DOJ's Investigation Of Reckitt's Suboxone Promotions Marks The Return Of The Big Settlement
$1.4b payment to settle investigation of marketing of opioid addition treatment is biggest for a pharma in several years.